-
-
-
-
-
-
-
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
-
-
-
-
-
-
-
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's T
-
-
-
-
-
-
-
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
-
-
-
-
-
-
-
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
-
-
-
-
-
-
-
Pacira BioSciences reports $726.4 million revenue for 2025
-
-
-
-
-
-
-
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
-
-
-
-
-
-
-
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
-
1,198,707 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

